Healthcare
BiomX Inc.(PHGE)
Live Price
Offline$0.52
-5.45% today
1Y Change
-93.72%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +20.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BiomX Inc. (PHGE) is a Healthcare stock with listed on AMEX. The stock last traded around $0.52 and down 93.7% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +20.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +20.6%, free cash flow +28.7% with operating margin 0.0% and ROIC -47.4%. Stock Foundry combines PHGE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +20.6%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -8.9% | +26.5% | -8.2% |
2026 Mar 24, 2026 | +0.0% | +0.6% | -22.8% | -70.6% |
2025 Nov 12, 2025 | +9.4% | -6.9% | -28.7% | -65.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHGE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHGE Max Drawdown
-96.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHGE and SPY.
Company Overview
BiomX Inc.
New York Stock Exchange American
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
- Leadership
- Michael Oster
- IPO Date
- Mar 13, 2019
- Employees
- 52
- Street Address
- 22 Einstein Street
- Mailing
- Ness Ziona, 7414003
- Region
- Ness Ziona, IL
- Reporting Currency
- USD
- Investor Line
- 972 7 2394 2377
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +20.6%
- Free Cash Flow
- +28.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -274.0%
- ROIC
- -47.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.87
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.